Education and Training
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progressive phenotype, HRCT images will be collected throughout the study for use in future research efforts.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
- Willing and able to provide informed consent
- Established a new diagnosis of IPF by the enrolling subspecialty center (as defined by
ATS/ERS/JRS/ALAT criteria)
- Age 30 years or older, or
- Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic
Non-Specific Interstitial, Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial
Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune
ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic
Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as
asbestosis with progressive phenotype
Exclusion Criteria:
- Malignancy, treated or untreated, other than skin or early stage prostate cancer,
within the past 5 years
- Currently listed for lung transplantation at the time of enrollment
- Currently enrolled in a clinical trial at the time of enrollment in this registry
Ages Eligible for Study
30 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kim Nguyen
650-723-0291
Not Recruiting